Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on developing therapies for immune dysregulation. Its lead program is AVTX-009, an anti-IL-1β monoclonal antibody being developed for hidradenitis suppurativa and other inflammatory diseases. The company's mission is to improve outcomes for patients with serious inflammatory and immune-mediated conditions.